This study is to assess the antitumor activity of 9-amino-20(s)-camptotecin administered as a 72 hour continuous infusion every 2 weeks as first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), to continue to describe the toxicities of 9-AC and to continue to investigate the clinical pharmacology of 9-AC and seek pharmacodynamic relationships between pertinent pharmacologic parameters, toxicity, and antitumor response.
Showing the most recent 10 out of 65 publications